End-to-end collaboration to transform biopharmaceutical development and manufacturing.

Area of Science:

• Biopharmaceutical Manufacturing
• Chemical Engineering
• Supply Chain Management

Background:

• The biopharmaceutical industry faces challenges in cost, flexibility, and supply chain efficiency.
• Existing manufacturing technologies often lack the adaptability required for diverse and evolving product portfolios.

Purpose of the Study:

• To outline a 10-year collaborative program for developing and commercializing integrated biopharmaceutical manufacturing technology.
• To achieve improved control, robustness, cost reduction, flexibility, and supply chain velocity.
• To focus on sustainable practices in raw material, component, and energy usage.

Main Methods:

• Organizing the program into workstreams: end-to-end control strategy, equipment flexibility, next-generation technology, sustainability, and a physical test bed.
• Integrating drug substance and drug product manufacturing elements.
• Focusing on synergistic elements like process intensification and improved robustness.

Main Results:

• Anticipated outcomes include reduced capital and operating costs.
• Enhanced flexibility to manage a diverse product portfolio under uncertain demand.
• Increased supply chain velocity and improved sustainability.

Conclusions:

• The integrated approach offers significant improvements over current biopharmaceutical manufacturing paradigms.
• Synergistic elements like process intensification and robustness are key drivers for cost reduction and efficiency.
• The program aims to transform the industry by enabling faster development and more secure, cost-effective supply.